Annenberg Center for Health Sciences at Eisenhower

Biologics in Severe Asthma: Optimizing Therapeutic Selection and Patient Outcomes

Overview / Abstract:	This case-based activity focuses on considerations, including phenotypes and biomarkers, in individualizing treatment with the 5 monoclonal antibodies currently approved for severe asthma in the United States. The role of shared decision-making is discussed as an approach to individualizing therapy and improving patient outcomes. Clinical criteria for assessing treatment response to biologic therapy and how to modify therapy when needed are also discussed.
Expiration	Dec 14, 2021
Discipline(s)	Physician CME
Format	Webinar / Webcast / Video
Credits / Hours	a maximum of 1.00 AMA PRA Category 1 Credit™.
Accreditation	ACCME
Presenters / Authors / Faculty	Reynold A. Panettieri, Jr, MD Vice Chancellor, Translational Medicine and Science Director, Rutgers Institute for Translational Medicine and Science Professor of Medicine, Rutgers University New Brunswick, New Jersey Emeritus Professor of Medicine, University of Pennsylvania
Activity Specialities / Related Topics	Allergies / Allergic Reactions, Immunology / Immunosuppression, Primary Care, Pulmonary Medicine / COPD
Sponsors / Supporters / Grant Providers	This activity is supported by an independent educational grant from Novartis Pharmaceuticals Corporation.
Keywords / Search Terms	Annenberg Center for Health Sciences at Eisenhower Asthma Severe Asthma Biologics Phenotypes Biomarkers Assessing Asthma Treatment Biologic Therapy Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map